Large, randomized clinical trials have demonstrated that the implantable cardioverter defibrillator (ICD) reduces sudden cardiac death mortality, and thereby all-cause mortality, in patients who have been resuscitated from an episode of spontaneous life-threatening ventricular tachycardia (VT) or ventricular fibrillation (VF [secondary prevention of sudden cardiac death]) (2) , and in certain patients deemed See page 908 to be at high risk of having an episode of life-threatening VT/VF (primary prevention of sudden cardiac death) (3) . The relative risk reduction in arrhythmic death in these trials approached 60% and was entirely responsible for a relative risk reduction in all-cause mortality of 30% (4) .
The patient populations in these trials were dominated by those with compromised left ventricular systolic function secondary to either atherosclerotic coronary artery disease or idiopathic congestive cardiomyopathy. Accordingly, unequivocal evidence for the ICD representing lifesaving therapy in patients with any of the many other predisposing causes of VT/VF does not exist. Nevertheless, it is common practice to prescribe an ICD for patients whose annual risk of sudden cardiac death is equal to or greater than the approximate 3% to 4% annual risk of sudden cardiac death observed in the control patient populations of these trials (2) (3) (4) (5) . Relative to the secondary prevention of sudden cardiac death, current guidelines (6) provide a Class I recommendation to insert an ICD in "patients who are survivors of cardiac arrest due to VF or hemodynamically unstable sustained VT after evaluation to define the cause of the event and to exclude any completely reversible causes." Relative to the primary prevention of sudden cardiac death, current guidelines (6) provide a Class I recommendation to insert an ICD only in patients well represented in the randomized ICD clinical trials discussed.
Nevertheless, Class IIa recommendations to insert an ICD are provided for a number of less common arrhythmogenic conditions that have not been studied in randomized controlled clinical trials. These guideline recommendations are predicated on either the assumption of or observational trial evidence that: 1) a patient population with an uncommon arrhythmogenic condition can be identified with a predicted sudden cardiac death probability similar to the 3% to 4% per year event rate seen in the control groups of the randomized ICD trials; 2) this sudden cardiac death risk is not transient or reversible; 3) ICD therapy is capable of terminating VT/VF and thereby preventing sudden death in this setting; and 4) there are not frequent competing causes of mortality that would negate any survival advantage for the prevention of sudden cardiac death. The current guidelines (6) are silent with respect to use of an ICD in patients with coronary artery vasospasm, presumably because these conditions have not yet been met.
Observational trials of patients with coronary artery vasospasm who are receiving medical treatment with calcium antagonists report an annual cardiac arrest or sudden cardiac death risk of approximately 0.6% per year (7 (8) . Standard medical therapy for patients with coronary artery vasospasm consists of calcium antagonist therapy with or without concomitant nitrate therapy, smoking cessation, avoidance of beta-blocker drug therapy, and use of an 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin) (9). Only very limited contemporary data are available regarding the annual risk of sudden cardiac death among patients with coronary artery vasospasm who have presented with an out-of-hospital cardiac arrest and then receive optimal medical therapy with respect to their subsequent annual risk of sudden death and with respect to the efficacy of ICD therapy in this setting.
In this issue of the Journal, Matsue et al. (10) provide the results of a retrospective observational trial focused on 23 apparently consecutive patients from 3 Japanese hospitals who had received a secondary prevention ICD after resuscitation from an episode of life-threatening VT/VF in the absence of structural heart disease or coronary artery disease who had spasm of a major epicardial coronary artery induced with acetylcholine challenge. Over a mean follow-up period of 2.9 years, 4 patients had an episode of VF appropriately treated by their ICD and survived, and 1 additional patient had a cardiac arrest secondary to pulseless electrical activity and survived. These data provide an estimate of the annual probability of sudden cardiac death secondary to VT/VF in such patients: approximately 6% per year. This estimate exceeds the 3% to 4% annual risk of the control patient populations of the randomized ICD trials. Although it is clear that incidence of the surrogate endpoint of appropriate ICD therapy for VT/VF exceeds that of the incidence of sudden cardiac death, the overestimate provided by use of this surrogate endpoint in this instance, where all treated events were VF, is not expected to be as large as the 2:1 ratio observed in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) study (5, 11) . These events occurred despite optimal medical therapy of coronary artery vasospasm (although 1 patient with ICD-treated VF had discontinued his medical treatment) and occurred in the absence of premonitory changes in the patients' symptomatic states. This evidence, that the risk of sudden cardiac death in this setting is not transient, reversible, or predictable despite medical therapy, is supported by other observational trials (7, 12, 13) . The results of the report of Matsue et al. (10) also indicate that ICD therapy is effective for the termination of VF and for the secondary prevention of sudden cardiac death in patients with coronary artery vasospasm, and that competing causes of mortality in these patients in the absence of significant structural coronary artery disease are infrequent.
These observations support the use of ICD therapy in patients with coronary artery vasospasm who have survived an episode of life-threatening VT/VF. Nevertheless, many questions remain. First, it is not yet clear that the risk of recurrent VT/VF is enduring in this patient population. Although is not wise to overinterpret the shape of a Kaplan-Meier curve, from the data presented by Matsue et al. (10) , all of the recurrent events occurred within the first 2 years of follow-up, and none of the patients with a recurrent event had a second recurrent event. Whether the apparent benefit of an ICD in this patient population is time limited can only be determined by very long-term follow-up.
Second, it is noteworthy that the patients described in the report of Matsue et al. (10) also had, in addition to the risk predictor of spontaneous life-threatening VT/VF, other risk factors for future adverse cardiac events including a high proportion (more than half) who had multivessel coronary spasm.
Third, this trial and most of the contemporary reports of large patient populations with coronary artery vasospasm have exclusively considered Japanese patients, raising the question as to the external validity of their results in other ethnic groups. Although it is clear that the incidence of coronary artery vasospasm is higher in the Japanese population than in the populations of North America or Western Europe (9), there is no compelling evidence that the natural history of a patient with documented coronary artery spasm and spontaneous life-threatening VT/VF differs by ethnicity or location.
Fourth, larger population of patients with coronary artery vasospasm treated with an ICD will be required to determine if there are unique potential complications of an ICD in this setting in addition to the previously reported possibility of ICD oversensing of the ventricular repolarization changes that accompany a spontaneous episode of coronary artery vasospasm (14) .
Finally, this report also suggests that there may be value in provocative testing for coronary artery spasm in patients who have experienced life-threatening VT/VF in the absence of an identifiable cause so that patients with demonstrated coronary artery spasm could also benefit from the advantages of vasodilator therapy. Although this association is not considered to be frequent in North America, a previous report from the West estimated that approximately one-third of patients with life-threatening VT/VF in the absence of structural heart disease have coronary artery spasm and silent myocardial ischemia responsible for their arrhythmia (15) .
